DE60134990D1 - Quinazolin-derivate als kinase inhibitoren - Google Patents

Quinazolin-derivate als kinase inhibitoren

Info

Publication number
DE60134990D1
DE60134990D1 DE60134990T DE60134990T DE60134990D1 DE 60134990 D1 DE60134990 D1 DE 60134990D1 DE 60134990 T DE60134990 T DE 60134990T DE 60134990 T DE60134990 T DE 60134990T DE 60134990 D1 DE60134990 D1 DE 60134990D1
Authority
DE
Germany
Prior art keywords
kinases
phosphorylation
pharmaceutically acceptable
acceptable salts
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134990T
Other languages
German (de)
English (en)
Inventor
Anjali Pandey
Robert M Scarborough
Kenji Matsuno
Michio Ichimura
Yuji Nomoto
Shinichi Ide
Eiji Tsukuda
Junko Irie
Shoji Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Millennium Pharmaceuticals Inc
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Millennium Pharmaceuticals Inc filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE60134990D1 publication Critical patent/DE60134990D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60134990T 2000-08-18 2001-08-17 Quinazolin-derivate als kinase inhibitoren Expired - Lifetime DE60134990D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22612200P 2000-08-18 2000-08-18
PCT/US2001/041752 WO2002016351A1 (en) 2000-08-18 2001-08-17 Quinazoline derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60134990D1 true DE60134990D1 (de) 2008-09-04

Family

ID=22847639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134990T Expired - Lifetime DE60134990D1 (de) 2000-08-18 2001-08-17 Quinazolin-derivate als kinase inhibitoren

Country Status (24)

Country Link
US (5) US6982266B2 (https=)
EP (3) EP1315715B1 (https=)
JP (1) JP5073147B2 (https=)
KR (1) KR100831116B1 (https=)
CN (1) CN100358890C (https=)
AT (1) ATE402169T1 (https=)
AU (1) AU8544901A (https=)
BR (1) BR0113356A (https=)
CA (1) CA2426440C (https=)
CY (1) CY1110460T1 (https=)
CZ (1) CZ304061B6 (https=)
DE (1) DE60134990D1 (https=)
DK (1) DK1315715T3 (https=)
EA (1) EA005809B1 (https=)
ES (1) ES2311023T3 (https=)
HU (1) HU228668B1 (https=)
IL (2) IL154514A0 (https=)
MX (1) MXPA03001359A (https=)
NO (1) NO323782B1 (https=)
NZ (1) NZ524461A (https=)
PT (1) PT1315715E (https=)
SI (1) SI1315715T1 (https=)
WO (1) WO2002016351A1 (https=)
ZA (1) ZA200301510B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354039T3 (es) 2000-08-18 2011-03-09 Millennium Pharmaceuticals, Inc. Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
WO2002016361A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
AU8544901A (en) * 2000-08-18 2002-03-04 Cor Therapeutics Inc Quinazoline derivatives as kinase inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
EP1490362A2 (en) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
ATE302771T1 (de) 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
AU2003256922A1 (en) * 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
JP4588447B2 (ja) 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
JP2008504292A (ja) * 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090029982A1 (en) * 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
JP2009502804A (ja) * 2005-07-20 2009-01-29 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの新規な結晶形
WO2007100880A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
JP5250901B2 (ja) * 2007-02-23 2013-07-31 学校法人慶應義塾 アニリノキナゾリン系化合物及びその用途
EP2139869A2 (en) * 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2370417A2 (en) * 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN102942529B (zh) * 2012-11-09 2015-06-24 贵州大学 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN115108999B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111773440B (zh) * 2020-05-22 2026-04-17 南京大学 一种基于类酶催化反应的抗凝血材料
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
NZ330571A (en) * 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
DE69943144D1 (de) * 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
EP1309567A2 (en) 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
ES2354039T3 (es) 2000-08-18 2011-03-09 Millennium Pharmaceuticals, Inc. Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
WO2002016361A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
AU8544901A (en) * 2000-08-18 2002-03-04 Cor Therapeutics Inc Quinazoline derivatives as kinase inhibitors
EP1490362A2 (en) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2003000188A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
NO323782B1 (no) 2007-07-02
AU2001285449B2 (en) 2007-04-05
HK1057206A1 (en) 2004-03-19
US7560461B2 (en) 2009-07-14
ZA200301510B (en) 2004-06-22
EP1964839A2 (en) 2008-09-03
EA200300265A1 (ru) 2003-12-25
CA2426440A1 (en) 2002-02-28
MXPA03001359A (es) 2004-12-13
CN100358890C (zh) 2008-01-02
KR20030082537A (ko) 2003-10-22
EP1964839A3 (en) 2008-11-05
HUP0302615A2 (hu) 2003-12-29
ATE402169T1 (de) 2008-08-15
JP5073147B2 (ja) 2012-11-14
JP2005501796A (ja) 2005-01-20
US8324205B2 (en) 2012-12-04
US20130274252A1 (en) 2013-10-17
KR100831116B1 (ko) 2008-05-20
HUP0302615A3 (en) 2008-03-28
AU8544901A (en) 2002-03-04
CA2426440C (en) 2011-03-15
US20050101609A1 (en) 2005-05-12
NO20030747L (no) 2003-04-14
PT1315715E (pt) 2008-10-30
EP2277877A1 (en) 2011-01-26
NO20030747D0 (no) 2003-02-17
US20100113468A1 (en) 2010-05-06
US20150133439A1 (en) 2015-05-14
EP1315715A1 (en) 2003-06-04
EP1315715B1 (en) 2008-07-23
CN1633431A (zh) 2005-06-29
DK1315715T3 (da) 2008-11-17
CZ2003765A3 (cs) 2004-08-18
WO2002016351A1 (en) 2002-02-28
BR0113356A (pt) 2004-04-20
US20050288297A1 (en) 2005-12-29
ES2311023T3 (es) 2009-02-01
CY1110460T1 (el) 2015-04-29
US6982266B2 (en) 2006-01-03
EA005809B1 (ru) 2005-06-30
CZ304061B6 (cs) 2013-09-11
IL154514A (en) 2011-03-31
NZ524461A (en) 2004-12-24
SI1315715T1 (sl) 2008-12-31
IL154514A0 (en) 2003-09-17
HU228668B1 (hu) 2013-05-28

Similar Documents

Publication Publication Date Title
ATE402169T1 (de) Quinazolin-derivate als kinase inhibitoren
WO2002072578A3 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
DK0882717T3 (da) Nitrogenholdige heterocykliske forbindelser
ATE541833T1 (de) Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
ATE381557T1 (de) Rho-kinase inhibitoren
DE60143204D1 (de) N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
ATE240328T1 (de) Substituierte azaoxindolederivate
WO2000043373A3 (en) Kinase inhibitors
WO2002016360A3 (en) Nitrogenous heterocyclic compounds
DE60144050D1 (de) (Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors
EA200870454A1 (ru) Способ ингибирования c-kit киназы
FR2725719B1 (fr) Diazepino-indoles inhibiteurs de phosphodiesterases iv
DE60144284D1 (de) Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
ATE421510T1 (de) Kompetitive atp-kinasehemmer
TH48285A (th) อะโทรปไอโซเมอร์ 3-เฮเทอโรอาริล 4(3h) ควินาโซลิโนน
TH75082A (th) สารประกอบ พิร์รอโลไทรแอซีนเป็นสารยับยั้งไคเนส
RU99116012A (ru) Гетероциклические производные карбоновой кислоты, их получение и их применение в качестве антагонистов рецепторов эндотелина

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP

Owner name: MILLENIUM PHARMACEUTICALS, INC., SOUTH SAN FRA, US

8364 No opposition during term of opposition